On June 17, 2019, the United States District Court for the District of Delaware, in Novartis Pharmaceuticals Corp. v. Accord Healthcare Inc., et al., No. 18-cv-01043, held that venue was not proper in Delaware over Mylan...more
6/27/2019
/ Abbreviated New Drug Application (ANDA) ,
Bristol-Myers Squibb ,
Dismissals ,
FRCP 12(b)(3) ,
Generic Drugs ,
Hatch-Waxman ,
Improper Venue ,
Mylan Pharmaceuticals ,
Novartis ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Patents ,
Principal Place of Business ,
TC Heartland LLC v Kraft Foods ,
Venue